Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

NCT02902042 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Encorafenib
DRUG: Binimetinib
DRUG: Pembrolizumab
DRUG: Pembrolizumab alone

Sponsor

Prof. Dr. med. Dirk Schadendorf